Free Trial

IceCure Medical Q4 2022 Earnings Report

IceCure Medical logo
$1.08 -0.04 (-3.57%)
(As of 12:01 PM ET)

IceCure Medical EPS Results

Actual EPS
-$0.11
Consensus EPS
-$0.09
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

IceCure Medical Revenue Results

Actual Revenue
$0.94 million
Expected Revenue
$1.00 million
Beat/Miss
Missed by -$60.00 thousand
YoY Revenue Growth
N/A

IceCure Medical Announcement Details

Quarter
Q4 2022
Time
N/A

Conference Call Resources

Conference Call Audio

Forced out of retirement by these trades (Ad)

You know, I never really intended to get in front of a camera and tell folks about a new market paradigm that I discovered. Even though I have a bright and shiny “resume,” I thought I’d left investing behind forever. And I was more than happy to be a stay-at-home dad… But then I discovered Gamma Pockets… and everything changed

Make sure to check out Gamma Pockets HERE while it’s still widely available 

IceCure Medical Earnings Headlines

Icecure Medical: Strong Growth and Regulatory Momentum Support Buy Rating
How Low-Cost Stocks Generate Monthly Income
Are you ready to transform your investment strategy and generate a steady monthly income? We’re excited to offer you our exclusive report, "Options Trading Strategy: 2 (Surprisingly) Low-Cost Stocks Primed for Generating Monthly Income," FREE!
IceCure Medical Sees Strong Growth Amid ProSense® Adoption
See More IceCure Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like IceCure Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IceCure Medical and other key companies, straight to your email.

About IceCure Medical

IceCure Medical (NASDAQ:ICCM), a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

View IceCure Medical Profile

More Earnings Resources from MarketBeat